News

A high concentration formulation of Sandoz’s biosimilar Hyrimoz (adalimumab-adaz) has been approved by the U.S. Food and Drug Administration (FDA) to treat ankylosing spondylitis (AS) and other conditions. The new citrate-free formulation (100 mg/mL) is expected to be available on July 1, according to Sandoz. It’s approved for seven…

Low levels of the protein DUSP22 in certain immune cells may contribute to more severe ankylosing spondylitis (AS), according to a new study. The findings suggest that measuring DUSP22 levels could be useful as a way to assess disease activity and responses to treatments, the researchers said, noting…

A new study has identified more than a dozen medications that may serve as treatments for osteoporosis in people with ankylosing spondylitis (AS). The medications target genes common to both osteoporosis and AS, but more studies will be needed to determine whether they can ease AS-associated osteoporosis. The study,…

People with ankylosing spondylitis (AS) are more likely to develop osteoporosis than the general population, and also seem to develop it earlier in life, according to data from a large medical database in Israel. The risk of the bone condition was particularly higher for women, older patients, and people…

The approved therapy Taltz (ixekizumab) can effectively ease symptoms of ankylosing spondylitis and related forms of arthritis that affect the spine, a new analysis shows. The study, “The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis,”…

Adults with ankylosing spondylitis and other forms of arthritis are significantly less likely to be employed than people without arthritis, according to a new analysis from the U.K. Results suggest the effect of arthritis on employment is especially pronounced in certain demographic groups, particularly women and people without college…

Ankylosing spondylitis (AS) patients 65 and older may be at an increased risk of certain blood cancers compared with older adults in the general population, according to a recent study. The risk for these cancers, however, was similar among AS patients and people with another inflammatory condition called inflammatory…

Amgen’s Amjevita, the first biosimilar to Humira (adalimumab) to receive approval by the U.S. Food and Drug Administration, is now available in the U.S. for the treatment of ankylosing spondylitis (AS) and other diseases. While the medication was initially approved in 2016, Amjevita is only now reaching…

Smoking and alcohol consumption are both associated with lower rates of peripheral symptoms in people with spondyloarthritis, which includes ankylosing spondylitis, a new study reports. The findings were somewhat surprising, researchers noted, as smoking has been linked to a greater risk of developing certain rheumatic diseases, and with more…

The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…